Star Combo Pharma Ltd. (AU:S66)
ASX:S66
Want to see AU:S66 full AI Analyst Report?
Top Page
Star Combo Pharma Ltd.
(Sydney:S66)
Select Model
Select Model
Rating:64Neutral
Price Target:
AU$0.24
▼(-3.60% Downside)
Action:Reiterated
Date:03/24/26
The score is primarily supported by the improved 2025 financial performance (strong margin rebound, low leverage, and strong free cash flow). Offsetting this is weaker technical momentum (negative MACD and trading below key moving averages) and only moderate valuation support (P/E ~21 with a modest ~1.85% yield).
Positive Factors
Profitability rebound
An 18.9% net margin in 2025 represents a material improvement in profitability, indicating successful pricing, cost control or product-mix improvements. Sustained higher margins bolster cash generation and return on capital, providing a durable buffer for reinvestment or shareholder returns if maintained.
Negative Factors
Revenue decline
Top-line fell ~6.3% in 2025 and longer-term revenue growth metrics are weak, implying the recent profit recovery is more margin-driven than volume-driven. Persistent revenue weakness limits scalability, increases reliance on margin improvements, and raises the risk that earnings gains may not be durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability rebound
An 18.9% net margin in 2025 represents a material improvement in profitability, indicating successful pricing, cost control or product-mix improvements. Sustained higher margins bolster cash generation and return on capital, providing a durable buffer for reinvestment or shareholder returns if maintained.
Read all positive factors
Star Combo Pharma Ltd. (S66) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$27.68M
Dividend Yield1.54%
Average Volume (3M)6.77K
Price to Earnings (P/E)21.2
Beta (1Y)-0.54
Revenue Growth-18.76%
EPS Growth504.55%
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.03
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Star Combo Pharma Ltd. Business Overview & Revenue Model
Company Description
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, ma...
How the Company Makes Money
Star Combo Pharma Ltd. generates revenue primarily from the manufacturing and sale of its health and wellness products, including vitamins, dietary supplements, and skincare lines. The company owns and operates facilities for in-house product deve...
Star Combo Pharma Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.84M | 27.81M | 26.02M | 24.70M | 22.88M | 26.72M |
| Gross Profit | 5.42M | 6.27M | 5.44M | 4.66M | 5.61M | 4.61M |
| EBITDA | 6.69M | 6.64M | 2.79M | -2.53M | -126.71K | -6.40M |
| Net Income | 5.39M | 5.25M | 747.33K | -4.00M | -696.35K | -7.88M |
Balance Sheet | ||||||
| Total Assets | 46.99M | 48.45M | 42.82M | 42.23M | 43.44M | 43.32M |
| Cash, Cash Equivalents and Short-Term Investments | 18.18M | 18.11M | 7.36M | 9.49M | 10.39M | 17.32M |
| Total Debt | 8.29M | 3.93M | 4.03M | 4.19M | 4.12M | 3.30M |
| Total Liabilities | 8.30M | 10.19M | 9.30M | 8.97M | 8.04M | 7.13M |
| Stockholders Equity | 38.54M | 38.08M | 33.32M | 33.09M | 35.41M | 36.19M |
Cash Flow | ||||||
| Free Cash Flow | 254.05K | 11.55M | -1.76M | -851.83K | -7.21M | -6.93M |
| Operating Cash Flow | 602.90K | 11.94M | -316.45K | 1.88M | 87.11K | 331.53K |
| Investing Cash Flow | -1.26M | -9.72M | -136.79K | -3.23M | -3.24M | -7.53M |
| Financing Cash Flow | -626.09K | -795.12K | -370.93K | -53.44K | -169.08K | -2.08M |
Star Combo Pharma Ltd. Technical Analysis
Negative
0.25
Price Trends
0.21
Negative
0.22
Negative
0.21
Negative
Market Momentum
>-0.01
Positive
36.58
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Negative. The current price of 0.25 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.21, and above the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.58 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:S66.
Star Combo Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$27.68M | 21.25 | 14.06% | 1.54% | -18.76% | 504.55% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
48 Neutral | AU$27.62M | -7.05 | -108.90% | ― | -7.01% | 26.92% | |
47 Neutral | AU$31.90M | -2.45 | -1964.93% | ― | -100.00% | 2.53% | |
46 Neutral | AU$115.48M | -7.39 | -164.12% | ― | -14.85% | -41.04% | |
45 Neutral | AU$18.28M | -0.26 | 2542.90% | ― | -47.12% | -18.92% |
* Consumer Defensive Sector Average
AU:S66
Star Combo Pharma Ltd.
0.21
0.04
28.12%
AU:ZNO
Zoono Group Limited
0.06
0.02
61.54%
AU:NC6
Nanollose Ltd.
0.08
0.03
56.00%
AU:SKN
Skin Elements Limited
―
―
―
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.12
0.09
300.00%
Star Combo Pharma Ltd. Corporate Events
Star Combo Pharma Files 2025 Half-Year Appendix 4D Report
Feb 25, 2026
Star Combo Pharma Ltd. has released its Appendix 4D half-year report for the six months ended 31 December 2025, covering the group’s financial statements, directors’ report, and auditor reviews. The publication of this statutory report...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.